CTLA4 Gene Polymorphism and Its Association with Disease Occurrence, Clinical Manifestations, Serum Markers and Cytokine Levels in SLE Patients from North India

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2022 Nov 17

PMID 36386077

Authors

Vikas Kailashiya

Usha Singh

Jyotsna Kailashiya

Affiliations

Soon will be listed here.

Abstract

Background: Cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or CD152 is an inhibitory receptor expressed constitutively on CD4+CD25+ T regulatory lymphocytes (Treg) and transiently on activated CD4+ and CD8+ T lymphocytes. Association of gene polymorphisms with Systemic Lupus Erythematosus (SLE) has been reported in south Indians, but not in north Indians. This study aims to investigate gene polymorphism and its association with the occurrence of SLE, its clinical manifestation and serological markers in north Indians.

Methods: This cross sectional study was done in a tertiary health care centre in north India. Patients reporting to the hospital and diagnosed with systemic lupus erythematosus were included in study. +49 A/G (snp- rs231775) gene polymorphism was analysed in 41 SLE patients and 21 matched healthy controls by real time PCR method. ANA (Antinuclear Antibody), anti dsDNA, Interferon-γ (IFN- γ), TGF-β, IL-10 were measured by ELISA kits. Complement (C3 and C4) and immunoglobulins (IgA, IgG, IgM) estimation were done with the turbidometry method. Chi-square test was used for comparison between groups and odds ratio with 95% confidence interval was calculated to estimate the associated risk.

Results: A/A genotype was most common (51.2%) followed by the A/G genotype (46.3%) and G/G genotype (2.4%, detected in only 1 patient). The frequency of A allele was 74.4%, while of G allele was only 25.6%. A/G genotype SLE patients showed a higher risk (odds ratio 37.5, 95% CI- 6.048-232.51) of developing edema compared to A/A genotype patients. There was no statistically significant association of various genotypes with the occurrence of SLE and serum markers.

Conclusions: A/A was the most common genotype in both SLE patients and healthy controls of north India. Contrary to the previous report in south Indians, there was no statistically significant association between genotype and occurrence of SLE in north Indians. Only the presence of generalised edema was found significantly associated with the A/G genotype.

Citing Articles

A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A.

Howard T, Almieda M, Diego V, Viel K, Luu B, Haack K Res Sq. 2023; .

PMID: 37886476 PMC: 10602130. DOI: 10.21203/rs.3.rs-3371095/v1.

References

Holopainen P, Naluai A, Moodie S, Percopo S, Coto I, Clot F . Candidate gene region 2q33 in European families with coeliac disease. Tissue Antigens. 2004; 63(3):212-22. DOI: 10.1111/j.1399-0039.2004.00189.x. View

Schubert D, Bode C, Kenefeck R, Hou T, Wing J, Kennedy A . Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014; 20(12):1410-1416. PMC: 4668597. DOI: 10.1038/nm.3746. View

van Belzen M, Mulder C, Zhernakova A, Pearson P, Houwen R, Wijmenga C . CTLA4 +49 A/G and CT60 polymorphisms in Dutch coeliac disease patients. Eur J Hum Genet. 2004; 12(9):782-5. DOI: 10.1038/sj.ejhg.5201165. View

Barreto M, Santos E, Ferreira R, Fesel C, Fontes M, Pereira C . Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004; 12(8):620-6. DOI: 10.1038/sj.ejhg.5201214. View

Rowshanravan B, Halliday N, Sansom D . CTLA-4: a moving target in immunotherapy. Blood. 2017; 131(1):58-67. PMC: 6317697. DOI: 10.1182/blood-2017-06-741033. View

Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I . Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000; 18(5):565-70. View

Ulker M, Yazisiz V, Sallakci N, Avci A, Sanlioglu S, Yegin O . CTLA-4 gene polymorphism of exon 1(+49 A/G) in Turkish systemic lupus erythematosus patients. Int J Immunogenet. 2009; 36(4):245-50. DOI: 10.1111/j.1744-313X.2009.00856.x. View

Houssiau F, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer J, Renauld J . Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995; 4(5):393-5. DOI: 10.1177/096120339500400510. View

Lee Y, Harley J, Nath S . CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet. 2005; 116(5):361-7. DOI: 10.1007/s00439-004-1244-1. View

10.

Larsen C, Beggs M, Saeed M, Walker P . Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol. 2013; 24(5):722-5. PMC: 3636799. DOI: 10.1681/ASN.2012121180. View

11.

Almaani S, Meara A, Rovin B . Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016; 12(5):825-835. PMC: 5477208. DOI: 10.2215/CJN.05780616. View

12.

Chua K, Puah S, Chew C, Tan S, Lian L . Study of the CTLA-4 gene polymorphisms in systemic lupus erythematosus (SLE) samples from Malaysia. Ann Hum Biol. 2009; 37(2):274-80. DOI: 10.3109/03014460903325185. View

13.

Heward J, Gordon C, Allahabadia A, Barnett A, Franklyn J, Gough S . The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann Rheum Dis. 1999; 58(3):193-5. PMC: 1752847. DOI: 10.1136/ard.58.3.193. View

14.

Okamoto A, Fujio K, Okamura T, Yamamoto K . Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2012; 2011:463412. PMC: 3247013. DOI: 10.1155/2011/463412. View

15.

Butty V, Roy M, Sabeti P, Besse W, Benoist C, Mathis D . Signatures of strong population differentiation shape extended haplotypes across the human CD28, CTLA4, and ICOS costimulatory genes. Proc Natl Acad Sci U S A. 2007; 104(2):570-5. PMC: 1766426. DOI: 10.1073/pnas.0610124104. View

16.

Liu M, Wang C, Lin L, Wu C . CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus. 2001; 10(9):647-9. DOI: 10.1191/096120301682430249. View

17.

Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B . Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2002; 62(1):37-42. PMC: 1754302. DOI: 10.1136/ard.62.1.37. View

18.

Nistico L, Buzzetti R, Pritchard L, Van der Auwera B, Giovannini C, Bosi E . The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996; 5(7):1075-80. DOI: 10.1093/hmg/5.7.1075. View

19.

Theofilopoulos A, Koundouris S, Kono D, Lawson B . The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001; 3(3):136-41. PMC: 128889. DOI: 10.1186/ar290. View

20.

Ravirajan C, Wang Y, Matis L, Papadaki L, Griffiths M, Latchman D . Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford). 2004; 43(4):442-7. DOI: 10.1093/rheumatology/keh083. View